痴呆症患者与药物相关的不良事件 - 来自FDA不良事件报告系统的统计数据
Jieyu Mao1, Miyae Yamakawa1, Yasushi Takeya1
1Division of Health Sciences, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
The International journal of risk & safety in medicine
|November 7, 2025
概括
痴呆症患者 (PwDs) 的不良事件 (AEs) 通常被错误地归因. 这项研究发现了与特定药物相关的明显的AE模式,突出了需要更好的报告和审查,以确保痴呆症患者的安全.
科学领域:
- 药物监督 药物监督 药物监督
- 老年医学 老年医学
- 神经科学是一个神经科学.
背景情况:
- 痴呆症患者 (PwDs) 面临不良事件 (AE) 的风险增加,需要改善患者安全措施.
- 了解AE特征对于有效管理痴呆症护理至关重要.
研究的目的:
- 分析十年的FAERS数据,以确定痴呆症患者 (PwDs) 的AE症状模式.
- 在痴呆症患者群体中调查特定药物类别和副作用之间的关系.
主要方法:
- 对2014-2024年FAERS数据的分析,重点关注患有痴呆症的报告.
- 使用k-means集群来识别PWD中AEs的独特模式.
- 对报告特征,报告员类型和患者结果的描述性分析.
主要成果:
- 分析了涉及PWD的2万多份报告,其中住院和死亡是显著的结果.
- 常见的副作用包括死亡,侵略性和心.
- 胆酶抑制剂 (ChEIs),抗精神病药物和抗药物与神经系统和精神病AEs有关. 聚类揭示了年长的PWD对ChEIs (心血管) 和年轻的PWD对抗精神病药物 (死亡率,跌倒) 的特定风险.
结论:
- 在PWD中,副作用经常被错误地归因于衰老或疾病进展,可能掩盖与药物相关的原因.
- 加强AE报告,提高公众意识,定期药物审查和早期检测培训对于安全的痴呆症管理至关重要.
更多相关视频
04:13Using a Real-Time Locating System to Measure Walking Activity Associated with Wandering Behaviors Among Institutionalized Older Adults
Published on: February 8, 2019
7.2K
05:51Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.3K
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drug Dosing: Geriatric Patients
215
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
215
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
Dementia
503
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
503
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
